09-10, 10:45–11:30 (Europe/Istanbul), Young IFOS 1 (ICC - B3 Floor - 3B/63)
Jerome R. Lechien is head and professor of general surgery at the University of Mons. He is otolaryngologist with fellowship in laryngology and robotic head and neck surgery.
- Challenges Affecting ENT And Phoniatrics Practice In Underpriviliged World
- Practical Management Of Laryngopharyngeal Reflux Disease
- Diagnosis And Treatment Of Reflux: What Is Coming
- Platelet-Rich Plasma Injections Into The Olfactory Clefts Of Patients With Olfactory Dysfunction: An Updated Clinical Practice
- The Vision Of Olfaction Across The World
- From European And American Consensus To The IFOS Guidelines For Managing Laryngopharyngeal Reflux Disease
- Istanbul Consensus: Consensus Statement About Retrograde Cricopharyngeal Dysfunction (R-CPD) Definition And Mangement
- Feasibility Of Functional Preservation Surgery Of T3/T4 Head And Neck Cancer - A Pirouette Around The Cricoarytenoid Joint
Ali Bayram, MD, is an Associate Professor in the Department of Otolaryngology–Head and Neck Surgery at the University of Health Sciences, Kayseri Faculty of Medicine, Türkiye. He completed his medical education and residency training at Erciyes University.
Dr. Bayram has extensive clinical experience in head and neck surgery and has participated in several national and international observerships. His academic interests include head and neck oncology, otology, and scientific publishing.
He has authored numerous national and international publications and book chapters, contributing actively to the scientific literature in otorhinolaryngology. Dr. Bayram also serves as an Associate Editor of the Turkish Archives of Otorhinolaryngology and has been a reviewer for multiple international journals.
In addition to his academic and editorial roles, he is actively involved in professional organizations and currently serves as the Vice President of the Turkish School of Head-Neck and Thyroid Surgery.
- Management Of Post Chemoradiation Dysphagia In Head And Neck Cancers
- Malignancy Of Parotid Gland: A Surgical Dilemma
- Management Of Locally Advanced Thyroid Carcinoma
- Swallowing Assessment-1
- Neuromonitoring And Signal Loss Management In Thyroidectomy
- Management Of Thyroid Cancers Under Nerve Monitoring At The Otolaryngology Deparment Of A Tertiary Hospital In Jordan
- Avoidance Of Bilateral Vocal Cord Palsy After Thyroidectomy: What Are The Nuances?
Dr. Yilai Shu is a physician-scientist in the department of otolaryngology at Eye & ENT Hospital of Fudan University. He obtained both an M.D. and Ph.D. degree in otolaryngology. From 2010 to 2014, he studied as a PhD student in the joint training program and continued his research as a postdoctoral fellow at Massachusetts Eye and Ear-Harvard Medical School. Now, he serves as the vice president of Eye & ENT Hospital of Fudan University and Director of the Diagnosis and Treatment Center for Hereditary Deafness. His clinical interests are Otology and Neurotology. He is an expert in gene therapy and translational medicine of hereditary deafness based on gene replacement or CRISPR/Cas9 gene editing, hair cell regeneration in the inner ear, and hearing protection. He has developed a gene therapy candidate drug—AAV-hOTOF—for the treatment of hearing loss caused by genetic defects and successfully spearheaded the world’s first clinical trial in this groundbreaking field. He was awarded the 2025 ARO Award for Clinical Innovation and the XPLORER PRIZE for his commitment to advancing gene therapy treatments for hearing restoration.